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NEOPLASIA
Hypermethylation of E-cadherin in leukemia
John R. Melki, Paul C. Vincent, Ross D. Brown, and Susan J. Clark
E-cadheringeneisoftentermeda‘‘metas-
tasis suppressor’’ gene because the E-
cadherin protein can suppress tumor cell
invasion and metastasis. Inactivation of
the E-cadherin gene occurs in undifferen-
tiated solid tumors by both genetic and
epigenetic mechanisms; however, the
role of E-cadherin in hematologic malig-
nancies is only now being recognized.
E-cadherin expression is essential for
erythroblast and normoblast maturation,
yet expression is reduced or absent in
leukemic blast cells. This study examined
the messenger RNA (mRNA) and protein
expression of the E-cadherin gene in
bone marrow and blood samples from
normal donors and patients with leuke-
mia. We found that all normal donor
samples expressed E-cadherin mRNA,
whereas both samples of acute myelog-
enous leukemia and chronic lymphocytic
leukemia had a signiﬁcant reduction or
absence of expression. However, normal
blast counterparts expressed only a low
level of E-cadherin surface protein. So-
dium bisulphite genomic sequencing was
used to fully characterize the methylation
patterns of the CpG island associated
with the E-cadherin gene promoter in
those samples with matched DNA. All of
the normal control samples were essen-
tially unmethylated; however, 14 of 18
(78%) of the leukemia samples had abnor-
mal hypermethylation of the E-cadherin
CpG island. In fact both alleles of the
E-cadherin gene were often hypermethyl-
ated. We conclude the E-cadherin gene is
a common target for hypermethylation in
hematologic malignancies. (Blood. 2000;
95:3208-3213)
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Introduction
The E-cadherin gene (E-cad) on chromosome 16q22.1 encodes a
protein product important in the maintenance of the epithelial
phenotype mediated by a Ca11-dependent, homotypic cell-cell
adhesion (reviewed in reference 1). The gene has been termed a
‘‘metastasis suppressor’’ gene, because the E-cadherin protein can
suppress tumor cell invasion and metastasis.2 E-cad gene expres-
sion is reduced or silenced in carcinomas of the breast3 and liver4
and many cell lines including those from colon, stomach, and
prostate.5These carcinomas are generally poorly differentiated, and
reduced E-cad gene expression has been shown to correlate with
disease aggressiveness in prostate or breast cancer.2 E-cadherin
recently was found to have an unexpected role in hematopoiesis,
the E-cadherin protein being functionally involved in the matura-
tion of erythroid progenitors.6 Leukemic blasts, however, had no
detectable E-cad gene in acute lymphoblastic leukemia (ALL),
chronic myeloblastic leukemia (CML), and acute myeloblastic
leukemia (AML).7
The underlying mechanism of reduced or absent E-cad gene
expression in solid malignancies is not clear; however, trans-acting
pathways,8 allelic loss, 9 chromatin rearrangement,10 mutation,11
and hypermethylation3-5,12 of the cytosine residues in the CpG-rich
promoter regions (CpG islands) have all been implicated. Normal
cytosine methylation patterns are established early in development
by the processes of demethylation and de novo methylation
primarily at the cytosines of CpG dinucleotides (reviewed in
reference 13). These methylation patterns are faithfully maintained
through subsequent cell division by the DNA methyltransferase
enzyme (DNA MTase).14 Changes in DNA cytosine methylation
patterns are common in solid and hematologic malignancies, with
both hypomethylation and hypermethylation15,16 and a concurrent
increaseinthelevelsofDNAMTase.17Itistheaberranthypermeth-
ylation of CpG islands that is of particular interest to cancer biology
because there is a strong association with gene inactivation.18Although
most CpG dinucleotides in a normal cell are methylated, the CpG
dinucleotides comprising CpG islands are essentially unmethylated in
all tissues,19 but appear to become hypermethylated in speciﬁc tumor
suppressor genes in most malignancies including leukemia.15,18
Because changes in methylation patterns are common in
leukemia, we determined the role that DNAmethylation might play
in the reduction of E-cad gene expression in leukemic blast cells. In
this report, we conﬁrm a reduction or silencing of the expression
levels of E-cad mRNA in blood and bone marrow from patients
with leukemia when compared with normal donors. We also
determined the detailed methylation patterns of 29 CpG sites in the
E-cad gene CpG island using the technique of sodium bisulphite
genomic sequencing,20-22 and show that bi-allelic hypermethylation
of the E-cad gene CpG island is common in leukemia.
Materials and methods
Tissue samples
Blood samples obtained by venous aspiration or bone marrow samples
obtained by aspiration were collected from patients presenting with either
AML,ALL, or CLL. Lymphocytes were isolated from the blood samples by
a Ficoll-Paque gradient as per manufacturer’s instructions (Amersham
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3208 BLOOD, 15 MAY 2000 x VOLUME 95, NUMBER 10Pharmacia Biotech AB, Uppsala, Sweden), and bone marrow cells were
collected by centrifugation following lysis in hypotonic lysis buffer. The
proportion of marrow blasts, where known, was more than 70%. The bone
marrow used as a normal control was aspirated from the sternal cavity from
patients undergoing cardiac surgery who had given prior informed consent,
and the normal blood was obtained from regular donors to the blood bank.
The study was approved by the Ethics Committee of Royal Prince Alfred
Hospital. DNAand RNAwere isolated using TriZOL reagent (Gibco-BRL,
Life Technologies, Gaithersburg, MD).
mRNA expression analysis (reverse transcriptase-polymerase
chain reaction [RT-PCR])
Complementary DNA (cDNA) was reverse transcribed from 1 to 2 µg of
total RNA in a 25-µL reaction using AMV reverse transcriptase (Promega,
Madison, WI) as per the manufacturer’s instructions. The reaction was
primed with 0.5 to 1 µg of random hexamers (Boehringer, Mannheim,
Germany). Both E-cadherin and transferrin receptor RT-PCR reactions used
the same cDNA synthesis. The PCR reactions were performed in volumes
of 25 µL consisting of 200 µmol/L dNTPs, 100 ng primers, 1.75 mmol/L or
2.0 mmol/L MgCl2 (for E-cadherin and transferrin receptor, respectively),
1.0 µCi [33P]-a dATP, and 2 units AmpliTaq DNA polymerase (Perkin-
Elmer, Norwalk, CT) with 1 µL (transferrin receptor) or 2 µL (E-cadherin)
of cDNA in the manufacturer’s buffer (Perkin-Elmer). Transferrin receptor
was ampliﬁed to control for RNA integrity. The primers used for the
ampliﬁcation of transferrin receptor mRNA were Trans58 (1764-1786):
CTGTTGTATACGCTTATTGAGAA and Trans38 (2064-2086): CTAAC-
CCATGATGTTGAATTGAA; the primer coordinates in parentheses refer
to accession number X01060. The primers for the ampliﬁcation of E-cad
gene mRNA were Ecad3 (2071-2094): GGTGGGTGACTACAAAAT-
CAATCT, and Ecad2 (2357-2380): TTCTCCGCCTCCTTCTTCATCATA,
accession number Z13009. Reactions were performed in a Hybaid
DNA Thermal Cycler (Ashford, UK) under the following conditions:
E-cadherin—96°C/4 minutes for 1 cycle; 95°C/60 seconds, 62°C/90
seconds, 72°C/90 seconds for 5 cycles; 95°C/60 seconds, 64°C/60 seconds,
72°C/60 seconds for 25 cycles; 72°C/180 seconds for 1 cycle. Transferrin
receptor: 96°C/4 minutes for 1 cycle; 95°C/60 seconds, 60°C/90 seconds,
72°C/90 seconds for 5 cycles; 95°C/60 seconds, 60°C/60 seconds, 72°C/60
seconds for 25 cycles; and 72°C/180 seconds for 1 cycle. Products were
electrophoresed on a 6% acrylamide gel, dried, and exposed to a Phosphor-
Imager (Molecular Dynamics, Sunnyvale, CA).
Surface expression analysis (FACS)
To determine the extent to which normal counterpart cells express
E-cadherin protein, 1 mLnormal mononuclear bone marrow cells separated
by centrifugation through Ficoll-Paque or 5 mLnormal blood was analyzed.
The cells were incubated with 20 µL rabbit polyclonal anti-E-cadherin
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) according to the
manufacturer’s directions, and visualized by adding 2 µLof sheep antirabbit
ﬂuorescein isothiocyanate (FITC)-labeled monoclonal antibody (Silenus,
Hawthorn, Australia). The cells were labeled with 10 µL phycoerythrin-
labeled murine monoclonal anti-CD34 antibody (Becton Dickinson, Moun-
tain View, CA) according to the manufacturer’s directions, and a second
tube was labeled using 20 µL phycoerythrin-labeled murine monoclonal
anti-glycophorin A antibody (DAKO, Carpinteria, CA). Flow cytometric
datawereacquiredonaCoulterEPICS-XL-MCLﬂowcytometer(Beckman-
Coulter, Hialeah, FL).
Methylation analysis
Bisulphite genomic sequencing was used to determine the methylation
pattern of the E-cadherin CpG island. The bisulphite reaction was carried
out for 16 hours at 55°C on 1 to 2 µg of Hind III digested patient DNA in
18 µL, under conditions described in Clark et al.21 Following bisulphite
conversion, the DNA was ethanol precipitated, dried, and resuspended in
100 µL TE (10 mmol/L Tris-HCl, pH 8; 1 mmol/L EDTA) and stored
at 220°C.
The CD341 cells were isolated from normal bone marrow and
peripheral blood using Dynabeads M-450 Rat antimouse IgG1 magnetic
beads (Dynal, Carlton, Australia), according to the manufacturer’s instruc-
tions (direct technique). A total of 3.75 µg murine monoclonal anti-CD34
antibody (Becton Dickinson) was conjugated to 200 µL Dynabeads, and
100 µL was added to each bone marrow and peripheral blood sample. The
CD34
1 cells were lysed while still conjugated to the Dynabeads by the
addition of 200 µL cell lysis buffer (100 mmol/L Tris-HCl, pH 8, 3%
sodium dodecyl sulfate (SDS), 50 mmol/LEDTA, 200 µg/mLProteinase K)
and an 18-µL aliquot was treated with sodium bisulphite as outlined above.
A nested PCR was performed using the following primers: outer1
(791-820): ATTTAGTGGAATTAGAATAGTGTAGGTTTT; outer2 (1139-
1165): CTACAACTCCAAAAACCCATAACTAAC; inner1M13 (841-
858): TGTAAAACGACGGCCAGTTTAGTAATTTTAGGTTAGAGGG;
inner2 (1139-1165): CTACAACTCCAAAAACCCATAACTAAC; acces-
sion number L34545. The incorporation of the (221)M13 universal
primer sequence into the inner primer enabled direct sequencing of the
PCR product.
The nested PCR ampliﬁcations were performed on 2 µL of bisulphite-
treated genomic DNA in a reaction mix containing 200 µmol/L of each of
the 4 dNTPs and 2 U AmpliTaq DNA polymerase (Perkin-Elmer). The
reactions were performed in 50-µL reactions containing 67 mmol/L Tris,
16.6 mmol/L ammonium sulfate, 1.7 mg/mL bovine serum albumin, 10
mmol/L b-mercaptoethanol in TE buffer (10 mmol/LTris-HCl, pH 8.0; 0.1
mmol/L EDTA) and 300 ng of each primer. Reactions were cycled in a
Hybaid DNA Thermal Cycler using the following cycling conditions:
96°C/3 minutes for 1 cycle; 95°C/1 minute, 55°C/2 minutes, 72°C/3
minutes for 5 cycles; 95°C/1 minute, 55°C/2 minutes, 72°C/2 minutes for
23 cycles; and 72°C/4 minutes for 1 cycle. The primers used were shown to
amplify methylated and unmethylated DNA without notable bias under
these PCR conditions.23
Direct sequencing
The PCR products were puriﬁed using a WIZARD PCR clean-up column
(Promega), and direct PCR sequencing reactions were performed using a
PRISM Dye Primer Cycle sequencing kit (221M13 Fwd) with AmpliTaq
FS (Perkin-Elmer) and electrophoresed using an automated 373A DNA
Sequencer (ABI). Sequencing reactions were performed as recommended
by the manufacturer. The amount of methylcytosine of each CpG dinucleo-
tide was quantitated by comparing the peak height of the cytosine signal
with the peak height of the cytosine plus thymine signal.
Statistical analysis
Statistical analysis was performed using InStat v2.02 (Macintosh), applying
a nonparametric unpaired 2-tailed test.
Results
E-cad gene expression
To determine the expression levels of E-cad gene mRNAin normal
and leukemic cells, we used RT-PCR, coamplifying transferrin
receptor (CD71) cDNA as a control for RNA integrity and cDNA
synthesis. The transferrin receptor gene was chosen because it is
widely expressed on hematopoietic progenitors,24 and therefore
any differential E-cad gene expression would be the result of
selective E-cad gene silencing. As shown in Figure 1, all the
normal bone marrow and blood controls expressed E-cadherin
mRNA, whereas both AML and CLL samples showed an overall
reduction or absence of expression.
To clarify whether the normal counterparts of leukemic cells
express E-cadherin protein on the cell surface, we assayed protein
expression in CD341 cells by ﬂow cytometry. Figure 2 shows that
of the CD341 cells in the normal bone marrow, 12% expressed
E-cadherin protein on the cell surface. We found that the majority
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pressed E-cadherin protein, similar to the ﬁndings of Buhring and
coworkers.7 It is likely that the erythroid component contributed to
the high level of E-cadherin mRNA expression in unseparated normal
marrowcells,althoughalowproportionofthenormalblastcounterparts
did express E-cadherin protein. Only a small proportion of CD191
lymphocytes from normal (4%) or CLL blood (1%) expressed E-
cadherin protein on the cell surface (Figure 2). The substantial
E-cad gene mRNA expression in the Ficol-separated fraction of
normal blood may have been due to contaminating monocytes.
Methylation proﬁle of the E-cadherin gene CpG island
We determined the methylation proﬁle of the E-cad gene CpG
island from patient samples and normal controls that had matched
DNA, to look for a possible mechanism that was responsible for the
reduction in E-cadherin expression. The E-cad gene has an
associated CpG island that incorporates the promoter, exon 1, and
part of intron 1.25 The CpG island also contains the 2191 minimal
promoter region important to E-cad gene expression,5 and other
transcription-enhancing factors such as Sp1, E-Pal, and GC re-
gion10 (Figure 3). It is known that artiﬁcial methylation of the Hpa
II sites, within this CpG island, is sufficient to inhibit transcription.5
However, previous studies have used methylation speciﬁc PCR
(MSP) and Southern blot analysis that do not give information on
individual CpG sites.26,27 We have determined the methylation
status of 29 CpG sites located within the CpG island by bisulphite
genomic sequencing to see if any CpG sites were preferentially
methylated, particularly those comprising transcription factor bind-
ing sites. To estimate the methylation levels at each CpG site,
within the population of molecules ampliﬁed, we used direct PCR
sequencing. Examples of the direct sequencing proﬁles, containing
the cytosine versus thymine tracks used for quantitation, are shown
in Figure 4. It is important in quantitative analysis to ensure that
both methylated and unmethylated molecules amplify in propor-
tion.Therefore,PCRconditionswereoptimizedtoensurerepresen-
tative ampliﬁcation of methylated and unmethylated molecules in
the PCR product, as shown in Figure 4A.23
Six normal, 10AML, and 4 CLLsamples that had been assessed
for E-cad gene expression by RT-PCR also had matched DNA that
was available for methylation analysis. In addition, N40 (normal),
R36 (AML), R124 (CLL), and 2 ALL patients who did not have
corresponding RNA were analyzed for DNA methylation. Of the 7
normal bone marrow samples, only 1 (N34) of 7 (14%) had any
detectable methylation; however, the methylation was at a low
level (, 25%) and was restricted to only 5 of the 29 CpG sites
Figure 1. Expression analysis of the E-cad gene. (A) E-cadherin and transferrin
receptor RT-PCR products were ampliﬁed from bone marrow samples from normal
donors and patients with AML. (B) E-cadherin and transferrin receptor RT-PCR
products were ampliﬁed from blood samples from normal donors and patients with
CLL. E-cadherin PCR product is 310bp, and the transferrin receptor PCR product is
323 bp. The sample numbers are labeled above each lane (R, leukemic patient; N,
normal sample). The relative amount of E-cadherin expression versus transferrin
receptor expression (E-cad/transferrin) is expressed in the graph.
Figure2.Two-colorFACSanalysisforE-cadherincellsurfaceprotein.Coexpres-
sion of E-cadherin is shown for glycophorin A cells from normal bone marrow (A),
CD34 cells from normal bone marrow (B), CD19 cells from CLL blood (C), and CD19
cells from normal blood (D).
Figure 3. Map of the E-cad gene. (A) CpG island plot across the 58 promoter region
through to exon 2 (compiled from Genbank accession numbers L34545, L36526, and
L34937). The dark line is the %G1C, and the lighter line is the observed/expected
CpG density (O/E CpG). (B) Schematic representation of the gene, where the black
boxes represent the coding regions of exon 1 and exon 2. (C) The E-cad gene DNA
sequenceanalyzedbybisulphitegenomicsequencingfrombases863-1138(L34545),
incorporating 29 CpG sites. CpG dinucleotides are numbered below each site. The
Hpa II sites are underlined with a solid line, and the GC region is underlined with a
dotted line. Other features are boxed and labeled. An arrow represents the
transcription start site between CpG sites 15 and 16. The identiﬁed polymorphism (A
or T), after bisulphite sequencing, is at coordinate 862, and is immediately 58 to CpG
site 1. Bisulphite sequencing of this region identiﬁed an additional thymine at *, which
is not present in the published sequence (L34545).
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marrow were essentially unmethylated as shown by direct PCR
sequencing (Figure 5B). To determine if there was a low level of
methylation in individual molecules, the PCR fragment from the
CD341 cells was cloned and sequenced. Four of the 10 molecules
sequenced showed no evidence of methylation, whereas the other
molecules showed methylation at 1 to 3 individual CpG sites;
however, these sites varied between molecules (Figure 5B).
In contrast to the normal samples, 14 of 18 (78%) samples from
patients with leukemia displayed extensive methylation across the
E-cad gene CpG island (Figure 5A).Ahypermethylated phenotype
was found in cells from all leukemic subtypes, including 9 of 11
(82%)AMLpatients, 2 of 2 (100%)ALLpatients, and 3 of 5 (60%)
CLLpatients, with extensive hypermethylation spanning the E-cad
gene CpG island. The methylation patterns were heterogeneous,
ranging from limited methylation in some patients (eg, R36, R37,
R62, and R102) to methylation in each determinable CpG site (R76
and R99). The methylation patterns were not restricted to Hpa II or
transcription factor sites, but rather encompassed the entire re-
gion analyzed.
Bi-allelic E-cadherin methylation
In some patient samples, the degree of methylation at individual
CpG sites was high (50%-100%) in particular in the 38 region that
corresponds to exon 1 and the core of the CpG island. This high
degree of methylation reﬂected either that the methylation was
bi-allelic, or that 1 allele was deleted. To address whether
methylation of the E-cad gene was bi-allelic we identiﬁed an
informative polymorphism (T or A) within the sequenced region.
Approximately 50% of the normal and leukemia patients were
heterozygous for the polymorphism. We cloned and sequenced the
PCR products from 2 patients who were heterozygous for the
polymorphism, AML patient (R38) and ALL patient (R30). Figure
6 shows that methylation across the E-cad gene CpG island was
bi-allelic for both R38 and R30 because the clones containing
either the T or A polymorphism were methylated. In addition, the
degree of methylation, as well as the methylation proﬁle, appeared
to be similar for each allele. Although only a small number of
clones were analyzed, the level of methylation reﬂected the direct
sequencing methylation estimates. We also cloned and sequenced
the PCR product from anAMLpatient (R99) who was homozygous
for the polymorphism (Figure 6).All the molecules sequenced from
R99, except for 1, were heavily methylated. Because the methyl-
ation proﬁles from most of the molecules were similar, it is unclear
whether R99 had lost 1 allele, or whether hypermethylation was
also bi-allelic.
Figure 4. Direct PCR bisulphite sequencing proﬁles. Electrophoretograms of the
CpG region of the E-cad gene from CpG dinucleotides 11-17 show the T peaks
(dotted line) and C peaks (solid line) only. Note the sequence given within each panel
is that of the bisulphite-converted DNA, except for the CpG dinucleotides that are
shown as CG. The estimated amounts of methylcytosine, calculated by measuring
the peak height of the cytosine over the peak heights of the cytosine plus thymine, are
shown under each dinucleotide, where 2 indicates 0% methylation, 1 1% to 25%
methylation, 11 26% to 50% methylation, 111 51% to 75% methylation, and
1111 76% to 100% methylation. (A) 50% methylated control PCR reaction, as
described in Warnecke et al.23 (B) AML patient R99, with methylation throughout the
region. (C) Normal bone marrow control N43, with no methylation evident throughout
the region.
Figure 5. Methylation maps of E-cad gene CpG island. (A) Summary of the direct
PCR sequencing analysis for normal and leukemic samples.The sample number and
leukemia subtype (FAB classiﬁcation) are in the left column, and the CpG sites are
numbered across the top row.m represents up to 25% methylation,o represents
26% to 50% methylation, q represents 51% to 75% methylation, d represents
76% to 100% methylation, ands represents no methylation, as determined by direct
PCR sequencing. Absence of a score indicates that the methylation at that site was
unable to be determined due to enzyme stoppage in the sequence. (B) Methylation
results for CD341 cells. The top row represents the direct sequencing results,
followed by the methylation patterns for 10 cloned molecules. 1 indicates a
methylated CpG site and 2 indicates an unmethylated CpG site.
Figure 6. Bi-allelic methylation of E-cadherin. The methylation status at each CpG
site (1-29), as determined by cloning and sequencing the PCR products ampliﬁed
from bisulphite-treated DNA from R30, R38, and R99. The direct sequence methyl-
ation estimates are shown above (Figure 5). The polymorphism (A or T) identiﬁed in
each molecule is given in the last column.
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The E-cad gene is important in the metastatic potential of tumors as
its expression confers ‘‘metastasis suppressing’’ properties to the
malignant cells.1 Diminished E-cad gene expression is associated
with poorly differentiated aggressive carcinomas and is a prognos-
tic marker of poor clinical outcome in some tumors. The role of
E-cadherin in hematopoiesis and leukemia is not clear. Although
E-cadherin protein is mainly found on the cell surface of epithelial
cells, it has also been established that colony-forming units–
erythrocytes (CFU-E), normoblasts, and erythroblasts express
E-cadherin.6,7 Indeed erythroid progenitor cells are dependent on
E-cad gene expression for maturation.6 Our data show that a small
proportion of normal CD34 progenitor cells express E-cadherin on
the cell surface, similar to the results of others.6,7 However, cells
from patients with acute leukemia and CLLshow reduced or absent
E-cadherin mRNAexpression. Normal CD341 stem cells circulate
continuously in the blood,28,29 as do most leukemic cells, and it is
conceivable that this ability to leave the marrow microenvironment
could be related to decreased E-cad gene expression.
Reduced E-cad gene expression could be mediated by a number
of mechanisms including mutation, loss of heterozygosity, trans-
acting pathways, chromatin rearrangement, or DNA hypermethyl-
ation of the CpG island. Alterations in DNA methylation patterns
are commonly found in essentially all cancers, often with concomi-
tant changes in gene expression.18 Changes in methylation patterns
are common in leukemia16 and leukemic blast cells have an
elevated expression of DNA MTase.17 In this study, we analyzed
E-cad gene methylation across 29 CpG sites in the CpG-rich
promoter region using sodium bisulphite analysis. We found
hypermethylation in DNA from 78% of patients with leukemia,
including both acute and chronic types (AML,ALL, and CLL).The
methylation proﬁle across the CpG island was heterogeneous, with
no single CpG site consistently methylated. The transcription
enhancing elements Sp1, E-Pal, and the GC box did not appear to
differ in the amount of de novo methylation with respect to the rest
of the CpG island. This is similar to the methylation patterns we
have characterized for other genes in both cancer and normal
cells30-32 and supports the idea that it is not the methylation of
critical CpG sites in vivo that is important for gene silencing.
Furthermore, the density of methylation in the CpG island also did
not appear to be linked to gene expression because a small number
of patient samples had absent (eg, R113) or limited (eg, R126)
E-cadherin expression without corresponding methylation of the
CpG island promoter. These results support the possibility that
gene silencing is a precursor to aberrant CpG island methylation
in cancer.
The mechanism of CpG island methylation in cancer is unclear.
Graff et al26 have reported that E-cad gene CpG island methylation
is initiated from ﬂanking methylated Alu sequences, where the
methylation spreads into the body of the gene. Because the
methylation pattern found in our study was heterogeneous, it is not
clear if the methylation has spread from the ends of the CpG island
or was initiated within the CpG island. Our data support initiation
of methylation from within the CpG island because some samples
had no methylation in the beginning of the island that ﬂanks theAlu
sequences but moderate methylation within the body of the CpG
island,whereasothersampleswereextensivelymethylatedthrough-
out the region. In addition, a low level of methylation was found to
exist at individual CpG sites in some molecules in the normal
CD341 counterparts. This raises an interesting possibility that in
leukemia the hypermethylation of the E-cad gene CpG island may
be triggered by a combination of elevated expression of DNA
MTase17 and a low level of methylated CpG sites in the CpG island.
These CpG sites could act as seeds to aid methylation expansion
across the CpG island. The hypermethylated foci are found
scattered in different positions throughout the island in different
samples possibly reﬂecting the distribution of the initial CpG sites
that were methylated in the normal cell.
The results of this study have given an insight into the E-cad
gene expression in hematopoiesis and hypermethylation in leuke-
mogenesis. The E-cadherin protein was expressed at only low
levels in normal CD341 and CD191 cells, despite the E-cad gene
CpG island being essentially unmethylated. In contrast, hypermeth-
ylation in the E-cad gene CpG island was common in leukemic
cells and was frequently found to be methylated on both E-cad
gene alleles. Therefore, there must be a mechanism common in the
genesis of leukemia that renders the E-cad gene CpG island
promoter region susceptible to hypermethylation.
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